There is no need to increase the dose of medication as the patient’s epilepsy is well controlled on the current regimen. Switching from carbamazepine to lamotrigine is also unnecessary and not safer.

Pregnancy and breastfeeding can be a concern for women with epilepsy. It is generally recommended that women continue taking their medication during pregnancy, as the risks of uncontrolled seizures outweigh the potential risks to the fetus. However, it is important for women to take folic acid before pregnancy to reduce the risk of neural tube defects. The use of antiepileptic medication during pregnancy can increase the risk of congenital defects, but this risk is still relatively low. It is recommended to aim for monotherapy and there is no need to monitor drug levels. Sodium valproate is associated with neural tube defects, while carbamazepine is considered the least teratogenic of the older antiepileptics. Phenytoin is associated with cleft palate, and lamotrigine may require a dose increase during pregnancy. Breastfeeding is generally safe for mothers taking antiepileptics, except for barbiturates. Pregnant women taking phenytoin should be given vitamin K in the last month of pregnancy to prevent clotting disorders in the newborn.

A warning has been issued about the use of sodium valproate during pregnancy and in women of childbearing age. New evidence suggests a significant risk of neurodevelopmental delay in children following maternal use of this medication. Therefore, it should only be used if clearly necessary and under specialist neurological or psychiatric advice. It is important for women with epilepsy to discuss their options with their healthcare provider and make informed decisions about their treatment during pregnancy and breastfeeding.

Recommendations for Feeding Low-Birthweight Infants

Low-birthweight infants, those with a birthweight of less than 2,500 g, should be exclusively breastfed for the first six months of life, according to WHO recommendations. If the mother’s milk is not available, donor human milk should be sought. If that is not possible, standard formula milk can be used. There is no difference in the duration of exclusive breastfeeding between low-birthweight and normal-weight infants. Daily vitamin A supplementation is not currently recommended for low-birthweight infants, but very low-birthweight infants should receive daily supplementation of vitamin D, calcium, and phosphorus. Low-birthweight infants who are able to breastfeed should start as soon as possible after birth, once they are clinically stable.

What is the recommended prophylaxis for Rhesus sensitisation in a Rhesus negative mother with antepartum haemorrhage?

Antepartum haemorrhage increases the risk of Rhesus sensitisation and Rhesus disease of the newborn in subsequent pregnancies due to fetomaternal haemorrhage (FMH). The correct approach is to administer one dose of anti-D immunoglobulin immediately, followed by a Kleihauer test. This test detects fetal cells in the maternal circulation and estimates the volume of FMH, allowing for the calculation of additional anti-D immunoglobulin. While routine prophylaxis at 28 weeks should still be given, there is no such thing as an anti-D immunoglobulin infusion. These recommendations are based on the British Committee for Standards in Haematology guidelines for the prevention of haemolytic disease of the fetus and newborn.

Rhesus negative pregnancies can lead to the formation of anti-D IgG antibodies in the mother if she delivers a Rh +ve child, which can cause haemolysis in future pregnancies. Prevention involves testing for D antibodies and giving anti-D prophylaxis to non-sensitised Rh -ve mothers at 28 and 34 weeks. Anti-D immunoglobulin should be given within 72 hours in various situations. Tests should be done on all babies born to Rh -ve mothers, and affected fetuses may experience various complications and require treatment such as transfusions and UV phototherapy.

Breastfeeding is generally safe with most anti-epileptic drugs, including Lamotrigine which is commonly prescribed for seizures. It is a preferred option for women as it does not affect their ability to bear children. However, Carbimazole and Diazepam active metabolite can be passed on to the baby through breast milk and should be avoided. Isotretinoin effect on breastfed infants is not well studied, but oral retinoids should generally be avoided while breastfeeding.

Pregnancy and breastfeeding can be a concern for women with epilepsy. It is generally recommended that women continue taking their medication during pregnancy, as the risks of uncontrolled seizures outweigh the potential risks to the fetus. However, it is important for women to take folic acid before pregnancy to reduce the risk of neural tube defects. The use of antiepileptic medication during pregnancy can increase the risk of congenital defects, but this risk is still relatively low. It is recommended to aim for monotherapy and there is no need to monitor drug levels. Sodium valproate is associated with neural tube defects, while carbamazepine is considered the least teratogenic of the older antiepileptics. Phenytoin is associated with cleft palate, and lamotrigine may require a dose increase during pregnancy. Breastfeeding is generally safe for mothers taking antiepileptics, except for barbiturates. Pregnant women taking phenytoin should be given vitamin K in the last month of pregnancy to prevent clotting disorders in the newborn.

A warning has been issued about the use of sodium valproate during pregnancy and in women of childbearing age. New evidence suggests a significant risk of neurodevelopmental delay in children following maternal use of this medication. Therefore, it should only be used if clearly necessary and under specialist neurological or psychiatric advice. It is important for women with epilepsy to discuss their options with their healthcare provider and make informed decisions about their treatment during pregnancy and breastfeeding.

This patient is suspected to have a post-partum infection and sepsis in the puerperium, which can be fatal. A thorough examination is necessary to identify the source of infection, which is most likely to be the genital tract. Other potential sources include urinary tract infection, mastitis, skin infections, pharyngitis, pneumonia, and meningitis. The patient is experiencing abdominal pain, fever, and tachycardia, indicating the need for iv antibiotics and senior review. Regular observations, lactate measurement, and iv fluid support should be provided as per sepsis pathways. Blood cultures and vaginal swabs should be taken, and iv antibiotics should be administered within an hour of presentation. The patient is not a candidate for ambulatory treatment and needs to be admitted for further investigation and treatment.

Women with postpartum psychosis require hospitalisation, ideally in a Mother & Baby Unit, for close monitoring. This is a serious mental illness that should be treated as a medical emergency, and electroconvulsive therapy is not the next step in management.

Understanding Postpartum Mental Health Problems

Postpartum mental health problems can range from mild ‘baby-blues’ to severe puerperal psychosis. To screen for depression, healthcare professionals may use the Edinburgh Postnatal Depression Scale, which is a 10-item questionnaire that indicates how the mother has felt over the previous week. A score of more than 13 indicates a ‘depressive illness of varying severity’, with sensitivity and specificity of more than 90%. The questionnaire also includes a question about self-harm.

‘Baby-blues’ is seen in around 60-70% of women and typically occurs 3-7 days following birth. It is more common in primips, and mothers are characteristically anxious, tearful, and irritable. Reassurance and support from healthcare professionals, particularly health visitors, play a key role in managing this condition. Most women with the baby blues will not require specific treatment other than reassurance.

Postnatal depression affects around 10% of women, with most cases starting within a month and typically peaking at 3 months. The features are similar to depression seen in other circumstances, and cognitive behavioural therapy may be beneficial. Certain SSRIs such as sertraline and paroxetine may be used if symptoms are severe. Although these medications are secreted in breast milk, they are not thought to be harmful to the infant.

Puerperal psychosis affects approximately 0.2% of women and requires admission to hospital, ideally in a Mother & Baby Unit. Onset usually occurs within the first 2-3 weeks following birth, and features include severe swings in mood (similar to bipolar disorder) and disordered perception (e.g. auditory hallucinations). There is around a 25-50% risk of recurrence following future pregnancies. Paroxetine is recommended by SIGN because of the low milk/plasma ratio, while fluoxetine is best avoided due to a long half-life.

When a woman has gestational diabetes, it is important to control her blood glucose levels to prevent complications such as premature birth, stillbirth, and macrosomia. If diet and exercise changes along with metformin do not meet blood glucose targets, insulin therapy should be added, according to NICE guidelines. Sulfonylureas are not recommended for gestational diabetes as they are less effective than the metformin and insulin combination and have been shown to be teratogenic in animals. Metformin should not be stopped as it increases insulin sensitivity, which is lacking during pregnancy. SGLT-2 antagonists are also not recommended due to their teratogenic effects in animals. Continuing metformin alone for two weeks despite high blood glucose levels increases the risk of complications, so insulin therapy should be added at this stage.

Gestational diabetes is a common medical disorder affecting around 4% of pregnancies. Risk factors include a high BMI, previous gestational diabetes, and family history of diabetes. Screening is done through an oral glucose tolerance test, and diagnostic thresholds have recently been updated. Management includes self-monitoring of blood glucose, diet and exercise advice, and medication if necessary. For pre-existing diabetes, weight loss and insulin are recommended, and tight glycemic control is important. Targets for self-monitoring include fasting glucose of 5.3 mmol/l and 1-2 hour post-meal glucose levels.

Hypertension during pregnancy is a common occurrence that requires careful management. In normal pregnancies, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, in cases of hypertension during pregnancy, the systolic blood pressure is usually above 140 mmHg or the diastolic blood pressure is above 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from the initial readings may also indicate hypertension.

There are three categories of hypertension during pregnancy: pre-existing hypertension, pregnancy-induced hypertension (PIH), and pre-eclampsia. Pre-existing hypertension refers to a history of hypertension before pregnancy or elevated blood pressure before 20 weeks gestation. PIH occurs in the second half of pregnancy and resolves after birth. Pre-eclampsia is characterized by hypertension and proteinuria, and may also involve edema.

The management of hypertension during pregnancy involves the use of antihypertensive medications such as labetalol, nifedipine, and hydralazine. In cases of pre-existing hypertension, ACE inhibitors and angiotensin II receptor blockers should be stopped immediately and alternative medications should be prescribed. Women who are at high risk of developing pre-eclampsia should take aspirin from 12 weeks until the birth of the baby. It is important to carefully monitor blood pressure and proteinuria levels during pregnancy to ensure the health of both the mother and the baby.

Breech presentation occurs when the caudal end of the fetus is in the lower segment, and it is more common at 28 weeks than near term. Risk factors include uterine malformations, placenta praevia, and fetal abnormalities. Management options include spontaneous turning, external cephalic version (ECV), planned caesarean section, or vaginal delivery. The RCOG recommends informing women that planned caesarean section reduces perinatal mortality and early neonatal morbidity, but there is no evidence that the long-term health of babies is influenced by how they are born. ECV is contraindicated in certain cases, such as where caesarean delivery is required or there is an abnormal cardiotocography.

Minimizing Teratogenicity in Antiepileptic Medications for Women Wishing to Start a Family

For women with epilepsy who wish to start a family, it is crucial to minimize exposure to teratogenic antiepileptic medications while still controlling their seizures. Sodium valproate, a commonly used antiepileptic drug, is highly teratogenic and associated with congenital malformations and neural tube defects. Therefore, it is recommended to change medication prior to conception, as advised by an epilepsy specialist after a thorough evaluation of risks and benefits.

One option may be to add levetiracetam to the current medication regimen, as it is a pregnancy category C drug that may help control seizures. However, carbamazepine or lamotrigine may be preferred based on limited evidence.

Stopping sodium valproate and starting phenytoin is not recommended, as phenytoin also carries a significant risk of teratogenicity and has toxic and side effects.

Increasing the dose of sodium valproate is not advised, as it can negatively affect fetal neurodevelopment.

Similarly, stopping sodium valproate and adding phenobarbital is not indicated, as phenobarbital is also associated with an increased risk of teratogenicity.

Overall, it is important for women with epilepsy who wish to start a family to consult with an epilepsy specialist to evaluate and recommend appropriate antiepileptic medication changes to minimize teratogenicity while still controlling seizures.